| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC22A18AS |
| Uniprot No | Q8N1D0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-253 aa |
| 活性数据 | MGELPGSEGM WENCPLGWVK KKASGTLAPL DFLLQRKRLW LWASEPVRPQ PQGIHRFREA RRQFCRMRGS RLTGGRKGFG SSGLRFGRGG FSEEVMPQPV LKAMRCAEGA WWFSPDGPAG SSIWPAEG AEGLPGQLGR DRLEVVYSVP DNVPGQNGSR RPLVCKITGK CLSVCSEENA KAGGCSAFPL LLSQLGARMT GREHAHKGPE LTTPDSGLPR PPNPALAGFR ALAQHSPPLG TSTPSAVLLS T |
| 分子量 | 27.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC22A18AS蛋白的参考文献概要(基于现有学术研究整理，部分内容可能关联间接研究方向)：
---
1. **文献名称**: *SLC22A18AS Acts as a Tumor Suppressor in Lung Cancer via Regulation of Cellular Metabolism*
**作者**: Kim et al.
**摘要**: 本研究通过重组SLC22A18AS蛋白体外实验，发现其通过抑制糖酵解关键酶活性调控肿瘤细胞代谢，降低肺癌细胞的增殖和迁移能力，提示其作为肿瘤抑制蛋白的潜在机制。
---
2. **文献名称**: *Recombinant Expression and Functional Characterization of Human SLC22A18AS in Drug Transport*
**作者**: Zhang et al.
**摘要**: 作者在大肠杆菌系统中成功表达并纯化重组人SLC22A18AS蛋白，通过跨膜转运实验证实其具有底物特异性，可能参与抗癌药物(如顺铂)的细胞内转运，为药物耐药性研究提供依据。
---
3. **文献名称**: *Epigenetic Regulation of SLC22A18AS in Hepatocellular Carcinoma*
**作者**: Wang et al.
**摘要**: 本文发现SLC22A18AS蛋白在肝癌组织中表达显著下调，且其重组蛋白可诱导肝癌细胞凋亡。进一步分析表明，启动子区高甲基化导致其沉默，提示其在肝癌中的表观遗传调控机制。
---
4. **文献名称**: *Structural Insights into SLC22A18AS by Homology Modeling and Molecular Dynamics Simulation*
**作者**: Gupta & Sharma
**摘要**: 通过同源建模预测SLC22A18AS蛋白的三维结构，结合分子动力学模拟分析其可能的跨膜域及配体结合位点，为后续靶向该蛋白的功能研究提供理论支持。
---
**备注**：SLC22A18AS相关蛋白的直接研究较少，部分文献可能侧重于基因功能或与邻近基因(如SLC22A18)的关联。建议结合数据库(如UniProt、NCBI Gene)和最新预印本平台(如bioRxiv)获取更新进展。
The recombinant human SLC22A18AS protein is derived from the SLC22A18 antisense transcript, a non-coding RNA gene located on chromosome 11p15.5. This region is associated with genomic imprinting and linked to cancer susceptibility, particularly due to its proximity to tumor suppressor genes like HRAS and CDKN1C. SLC22A18AS, also known as IMPT1 or BWR1A, is implicated in regulating the expression of adjacent genes through epigenetic mechanisms, including chromatin remodeling and DNA methylation. Although originally annotated as non-coding, some studies suggest it may encode a small transmembrane protein belonging to the solute carrier (SLC22) family, potentially involved in organic substrate transport. Dysregulation of SLC22A18AS has been observed in cancers such as ovarian and breast cancer, where hypermethylation-induced silencing correlates with poor prognosis. Recombinant SLC22A18AS protein is typically expressed in vitro using systems like E. coli or mammalian cells to study its structural properties, interaction partners, and hypothesized roles in cell cycle regulation, apoptosis, or tumor suppression via pathways like p53. Its recombinant form enables functional validation of its disputed coding potential and exploration of therapeutic applications in imprinting-related disorders and oncology.
×
